|Leading Researchers Join Biogen Idec To Advance Drug Discovery For ...|
Through cutting-edge science and medicine, Biogen Idec discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. Founded in 1978 ...
Pharmaceutical Online (press release) - Thu, 23 Oct 2014 04:26
|Celgene (CELG) Revlimid Estimates, PT Lifted at Nomura|
We reiterate our Buy rating and view on CELG as our top large-cap pick for 2015, as positive Phase II GED-0301 data in Crohn's disease supported another multi-billion-dollar opportunity for Celgene and is the first of several pipeline catalysts that ...
StreetInsider.com (subscription) - Fri, 24 Oct 2014 06:41
|Search the Site|
According to GenomeDx, Decipher predicts the aggressiveness of a patient's disease based on genomic information that is distinct from that provided by PSA and other clinical risk factors. Clinical studies have demonstrated that Decipher can accurately ...
The Cancer Letter Publications - Fri, 24 Oct 2014 14:00
|Adaptive Biotechnologies Announces the Formation of a Hematologic ...|
Adaptive plans to work closely with the SAB to generate additional clinical evidence for the utility of clonoSEQ to measure relapse in patients with diseases such as Multiple Myeloma and Lymphoma, where MRD has traditionally been more difficult to ...
SYS-CON Media (press release) - Mon, 29 Sep 2014 08:47
|Genetic analysis of the pathogenic molecular sub-phenotype interferon-alpha ...|
Systemic lupus erythematosus (SLE) is a systemic autoimmune disorder characterized by involvement of multiple organ systems including skin, musculoskeletal, renal and hematologic systems. The pathogenesis of SLE is driven by a combination of both ...
Nature.com - Thu, 23 Oct 2014 01:58
|Pluristem Advances Its Second Major Cell Therapy Product Line From ...|
... today that it has completed development of its second major product line, and can now begin manufacturing the cells on a large-scale at its state-of-the art facility in order to meet demand for anticipated studies in a range of hematologic conditions.
GlobeNewswire (press release) - Mon, 20 Oct 2014 23:56
|Hematology & Stem Cell Transplantation Program|
True or False? Data from the Swedish Lymphoma Registry do not show favorable outcomes with up-front autologous hematopoietic cell transplantation (auto-HCT) in patients with peripheral T-cell lymphoma (PTCL), especially when etoposide was added to ...
Clinical Oncology News - Thu, 23 Oct 2014 20:56
|Immunomedics to Present Updated Clinical Results With Solid-Tumor Antibody ...|
Immunomedics also has a number of other product candidates that target solid tumors and hematologic malignancies, as well as other diseases, in various stages of clinical and pre-clinical development. These include bispecific antibodies targeting ...
CNNMoney - Wed, 22 Oct 2014 05:22